Ocular sarcoidosis: from clinical signs to targeted interventions
Abstract
Ocular sarcoidosis is a frequent manifestation of sarcoidosis and may occur most commonly affecting adults between 30 and 60 years old. Uveitis may be anterior, intermediate, posterior, or present as panuveitis, with marked heterogeneity in severity and clinical course. Diagnosis relies on a combination of compatible ocular findings and systemic investigations, including serum biomarkers, thoracic imaging, and histological evidence of noncaseating granulomas while carefully excluding infectious and neoplastic mimickers, particularly in atypical or corticosteroid-resistant cases. Bilateral, intermediate, posterior, and panuveitis often require systemic corticosteroids. Because of the unfavorable long-term safety profile of systemic corticosteroids, early introduction of steroid-sparing therapy is recommended in chronic, severe, or recurrent disease. Emerging therapies such as interleukin-6 receptor antagonists, Janus kinase inhibitors, and mTOR inhibitors represent promising options on top of methotrexate and TNF inhibitors for refractory sarcoid uveitis, although their use requires careful risk-benefit assessment and further validation in controlled trials.
Related
- Metagenomic next-generation sequencing of aqueous humor guides targeted therapy for Staphylococcus epidermidis endophthalmitis in chronic ocular graft-versus-host disease: a case report
- Mechanisms of inflammatory cell activation in periodontitis-induced bone destruction and advances in targeted interventions
- A Tissue-Targeted Immunotherapy Protects Against Recurrent Ocular Herpes Infection and Disease, and Alleviates the Associated Cognitive, Behavioral, and Social Deficits in a 'Humanized' HLA Transgenic Mouse Model of UVB-Induced Reactivation
- Metabolic Dysregulation and Metabolite-Targeted Interventions in Autism Spectrum Disorder: Mechanisms and Translational Perspectives
- Infection Dynamics and Clinical Signs of Bluetongue Virus Serotype 3 in Cattle and Transmission to Culicoides Vectors
BibTeX
@article{jammal2026ocular,
title = {{Ocular sarcoidosis: from clinical signs to targeted interventions}},
author = {Thomas El Jammal and Robin Jacquot and Stéphane Abramowicz and Laurent Kodjikian and Thibaud Mathis and Yasmine Serrar and Lucas Séjournet and Pascal Sève},
journal = {Current Opinion in Immunology},
year = {2026},
month = sep,
doi = {10.1016/j.coi.2026.102810},
url = {https://hal.science/hal-05751878v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Ocular sarcoidosis: from clinical signs to targeted interventions
AU - Thomas El Jammal
AU - Robin Jacquot
AU - Stéphane Abramowicz
AU - Laurent Kodjikian
AU - Thibaud Mathis
AU - Yasmine Serrar
AU - Lucas Séjournet
AU - Pascal Sève
PY - 2026
DA - 2026/09/16
JO - Current Opinion in Immunology
DO - 10.1016/j.coi.2026.102810
UR - https://hal.science/hal-05751878v1
AB - Ocular sarcoidosis is a frequent manifestation of sarcoidosis and may occur most commonly affecting adults between 30 and 60 years old. Uveitis may be anterior, intermediate, posterior, or present as panuveitis, with marked heterogeneity in severity and clinical course. Diagnosis relies on a combination of compatible ocular findings and systemic investigations, including serum biomarkers, thoracic imaging, and histological evidence of noncaseating granulomas while carefully excluding infectious and neoplastic mimickers, particularly in atypical or corticosteroid-resistant cases. Bilateral, intermediate, posterior, and panuveitis often require systemic corticosteroids. Because of the unfavorable long-term safety profile of systemic corticosteroids, early introduction of steroid-sparing therapy is recommended in chronic, severe, or recurrent disease. Emerging therapies such as interleukin-6 receptor antagonists, Janus kinase inhibitors, and mTOR inhibitors represent promising options on top of methotrexate and TNF inhibitors for refractory sarcoid uveitis, although their use requires careful risk-benefit assessment and further validation in controlled trials.
SN - 0952-7915
ER -